Open-label, Multicenter, Randomized, Cross-Over, Equivalence Study to Compare the Efficacy and Safety of Two Strengths of Pancreatin Enteric-Coated Capsules in Pancreatic Exocrine Insufficiency in Chinese Subjects
Latest Information Update: 07 Nov 2023
Price :
$35 *
At a glance
- Drugs Pancrelipase (Primary)
- Indications Exocrine pancreatic insufficiency; Pancreatitis
- Focus Therapeutic Use
- Acronyms CREON
- Sponsors Abbott Laboratories
- 23 Nov 2021 Planned End Date changed from 1 Aug 2021 to 30 Apr 2022.
- 23 Nov 2021 Planned primary completion date changed from 1 May 2021 to 1 Apr 2022.
- 26 Jun 2020 Planned End Date changed from 1 Aug 2020 to 1 Aug 2021.